Jupiter Neurosciences, Inc. – NASDAQ:JUNSW

Jupiter Neurosciences key metrics

Market Cap
 N/A
Enterprise value
 N/A
P/E
 N/A
EV/Sales
 N/A
EV/EBITDA
 N/A
Price/Sales
 N/A
Price/Book
 N/A
PEG ratio
 N/A
EPS
 N/A
Revenue
 N/A
EBITDA
 -4.30M
Income
 -5.09M
Revenue Q/Q
 N/A
Revenue Y/Y
 -85.97%
Profit margin
 -190.21%
Oper. margin
 -195.01%
Gross margin
 0%
EBIT margin
 -195.01%
EBITDA margin
 N/A

Get more financial ratios!

  • Every financial ratio you might need

  • 10 years history

  • Forward ratios (Analysts estimates)

Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

Jupiter Neurosciences stock price history

Jupiter Neurosciences stock forecast

Jupiter Neurosciences financial statements

Profit Margin

Jupiter Neurosciences, Inc. (NASDAQ:JUNSW): Profit margin
Dec 2021 0 -1.98M
Mar 2022 0 -623.50K
Jun 2022 233.28K -718.44K -307.98%
Sep 2022 0 -1.76M
JUNSW income statement history

Debt to Assets

Jupiter Neurosciences, Inc. (NASDAQ:JUNSW): Debt to assets
Dec 2021 667383 5.84M 875.81%
Mar 2022 404235 6.22M 1539.42%
Jun 2022 807322 7.00M 867.77%
Sep 2022 446104 6.40M 1436.1%
JUNSW balance sheet history

Cash Flow

Jupiter Neurosciences, Inc. (NASDAQ:JUNSW): Cash Flow
Dec 2021 -1.14M 0 287.5K
Mar 2022 -204.20K 0 0
Jun 2022 -510.19K 0 982.33K
Sep 2022 -339.96K 0 0
JUNSW cash flow history

Jupiter Neurosciences alternative data

Jupiter Neurosciences
Employees

Jupiter Neurosciences, Inc. (NASDAQ:JUNSW): Employee count
Aug 2023 5
Sep 2023 5
Oct 2023 5
Nov 2023 5
Dec 2023 5
Jan 2024 5
Feb 2024 5
Mar 2024 5
Apr 2024 5
May 2024 5
Jun 2024 5
Jul 2024 5

Jupiter Neurosciences other data

Frequently Asked Questions (FAQ)

  • When is Jupiter Neurosciences's next earnings date?

    Unfortunately, Jupiter Neurosciences's (JUNSW) next earnings date is currently unknown.

  • Does Jupiter Neurosciences pay dividends?

    No, Jupiter Neurosciences does not pay dividends.

  • What is Jupiter Neurosciences's stock symbol?

    Jupiter Neurosciences, Inc. is traded on the NASDAQ under the ticker symbol "JUNSW".

  • What is Jupiter Neurosciences's primary industry?

    Company operates in the Healthcare sector and Biotechnology industry.

  • How do i buy shares of Jupiter Neurosciences?

    Shares of Jupiter Neurosciences can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • How many employees does Jupiter Neurosciences have?

    As Jul 2024, Jupiter Neurosciences employs 5 workers.

  • When Jupiter Neurosciences went public?

    Jupiter Neurosciences, Inc. is publicly traded company for more then 3 years since IPO on 18 Jan 2022.

  • What is Jupiter Neurosciences's official website?

    The official website for Jupiter Neurosciences is jupiterorphan.com.

  • Where are Jupiter Neurosciences's headquarters?

    Jupiter Neurosciences is headquartered at 1001 North US HWY 1, Jupiter, FL.

  • How can i contact Jupiter Neurosciences?

    Jupiter Neurosciences's mailing address is 1001 North US HWY 1, Jupiter, FL and company can be reached via phone at +56 14066154.

Jupiter Neurosciences company profile:

Jupiter Neurosciences, Inc.

jupiterorphan.com
Exchange:

NASDAQ

Full time employees:

5

Industry:

Biotechnology

Sector:

Healthcare

Jupiter Neurosciences, Inc., a clinical stage research and development pharmaceutical company, develops resveratrol platform product primarily for the treatment of neuro-inflammation. It is developing JNS101 that is in Phase II trials for the treatment of Friedreich's Ataxia, a rare disease that causes damage to the nervous system, as well as mobility dysfunctions; and JNS102, which is in Phase II trials for the treatment of mucopolysaccharidosis Type I. The company is also developing JNS107 that is in Phase II trials for the treatment of MELAS Syndrome; and JNS108, which is in Phase II trials for the treatment of mild cognitive impairment/early Alzheimer's disease. In addition, it is developing JNS109 for amyotrophic lateral sclerosis; JNS110 for traumatic brain injury/concussion; and JNS120 for covid-19 treatment. The company was formerly known as Jupiter Orphan Therapeutics, Inc. and changed its name to Jupiter Neurosciences, Inc. in August 2021. The company was founded in 2016 and is headquartered in Jupiter, Florida.

+56 14066154
1001 North US HWY 1
Jupiter, FL 33477

:
:
: